ideasIdea
Borrow from past control arms to shrink the control group in phase 3
When the standard treatment has been given to thousands of similar patients in earlier trials, a new trial could randomise fewer people to it and lean on that history, as long as the old data still matches.
Hybrid control designs use Bayesian dynamic borrowing (power priors, meta-analytic-predictive priors, commensurate priors) from curated historical control arms and real-world cohorts to reduce concurrent control allocation to 1:2 or 1:3 while retaining randomisation. Borrowing is down-weighted automatically when the concurrent controls diverge from history. The FDA Complex Innovative Design programme has reviewed such designs; oncology uptake is limited.
Hypothesis
Hybrid-control phase 3 trials in well-characterised indications will reach the same decision as a conventional 1:1 trial with 25-40 percent fewer control patients and shorter accrual, and the borrowing weight will correctly fall when historical drift exists.
Rationale
Control-arm outcomes in first-line NSCLC, metastatic breast and CRC are stable across recent trials with the same regimen; requiring 400 fresh control patients every time is a cost paid by patients as well as sponsors.
What would test it
Re-analyse three completed phase 3 trials as if run with dynamic borrowing from pre-existing control data; confirm identical conclusions. Then run one prospective hybrid trial under the CID programme.
Maturity
early clinical
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.